<scp>TIM</scp>‐3 expression induces resistance to <scp>PD</scp>‐1 inhibitor in <scp>G‐CSF</scp>‐producing lung spindle cell carcinoma: A case report-Reference-Cited by-同舟云学术

TIM‐3 expression induces resistance to PD‐1 inhibitor in G‐CSF‐producing lung spindle cell carcinoma: A case report

Published:2023-11-05 Issue:36 Volume:14 Page:3556-3560
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Hayashi Fumiko¹,Akagi Kazumasa²³,Taniguchi Hirokazu²³^ORCID,Matsutake Toyoshi⁴,Kawahara Hiromi⁵,Sekine Ichiro⁶,Gyotoku Hiroshi¹²,Takemoto Shinnosuke¹²,Soda Hiroshi⁷^ORCID,Ashizawa Kazuto³⁸,Mukae Hiroshi¹²

Affiliation:

1. Department of Respiratory Medicine Nagasaki University Hospital Nagasaki Japan

2. Department of Respiratory Medicine Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

3. Clinical Oncology Center Nagasaki University Hospital Nagasaki Japan

4. Department of Respiratory Medicine Kouseikai Hospital Nagasaki Japan

5. Department of Internal Medicine Kouseikai Hospital Nagasaki Japan

6. Department of Pathology Kouseikai Hospital Nagasaki Japan

7. Department of Respiratory Medicine Sasebo City General Hospital Sasebo Japan

8. Department of Clinical Oncology Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

Abstract

AbstractLung spindle cell carcinoma is an aggressive subtype of pleomorphic lung cancer resistant to cytotoxic chemotherapy. Programmed cell death‐1 (PD‐1) inhibitors have been reported to have clinical effects in patients with spindle cell carcinoma; however, the resistance mechanism to PD‐1 inhibitors is yet to be fully elucidated. Herein, we report the case of an 88‐year‐old man with G‐CSF‐producing spindle cell carcinoma who acquired resistance to PD‐1/PD‐ligand 1 (L1) inhibitor in an early setting after a remarkable response. A histopathological review of the resistant specimen revealed a low count of CD8+ T cells and a predominant presence of M2 and TIM‐3+ macrophages, indicating the presence of an immunosuppressive microenvironment. Our findings suggest a novel resistance mechanism to PD‐1/PD‐L1 inhibitors in G‐CSF‐producing spindle cell carcinoma.

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.15149

Reference17 articles.

1. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

3. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

4. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

5. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling